GSK ends PhI­II Ze­ju­la tri­al af­ter run­ning in­to chal­lenges en­rolling pa­tients

GSK is shut­ter­ing a Phase III tri­al for its PARP in­hibitor af­ter run­ning in­to dif­fi­cul­ties re­cruit­ing enough el­i­gi­ble pa­tients.

The com­pa­ny will per­ma­nent­ly stop en­roll­ment …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER